Analyst Alerts Archives - Page 33 of 37

FridayFeb 24, 2017 11:23 am

NetworkNewsBreaks – Function(x), Inc. (NASDAQ: FNCX) Prices $4.8M Common Stock Offering, Hits 52-Week Low

Function(x) (NASDAQ: FNCX) shares dropped to $1.02 this morning after the social publishing and interactive media platform priced its underwritten public offering of 4,571,428 shares of its common stock at a public price of $1.05 per share. Additionally, the company has allowed the underwriters a 45-day option to purchase up to an additional 685,714 shares of common stock to cover over-allotments, if necessary. Before deducting underwriting discounts, commissions and other estimated offering expenses, the gross proceeds are expected to be approximately $4,800,000. Subject to customary closing conditions, the offering is expected to close on March 1, 2017. To view the…

WednesdayFeb 22, 2017 1:27 pm

NetworkNewsBreaks – Internap Corp. (NASDAQ: INAP) Shares Surge on $43M Private Placement, Revenue Guidance

Internap (NASDAQ: INAP) traded 26% higher mid-day after the company announced the private placement of approximately 23.8 million shares of its common stock at a price of $1.81 per share, for total gross proceeds of approximately $43 million. The funding in the private placement is provided by a group of investors that include affiliates of or funds managed by GAMCO Investors, Inc. and accounts advised by Avenir Corporation. The company intends to use the net proceeds of the offering to reduce debt. The settlement date for the transaction is February 27, 2017. Additionally, INAP reaffirmed guidance for 2016, including revenue…

WednesdayFeb 22, 2017 1:23 pm

NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Has ‘Buy’ Rating Reiterated by Aegis Capital; Reaches Key Milestone in ZX008 Dravet Syndrome Phase 3 Program

Zogenix (NASDAQ: ZGNX) has been reiterated at a 'Buy' rating and $28 price target by Aegis Capital Corp. The company recently announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome, a key milestone in the company’s phase 3 program. The two-cohort study will assess the pharmacokinetic and safety profile of single doses of ZX008, clobazam and valproate when added to stiripentol, followed by an evaluation of the efficacy, safety and tolerability of ZX008 as adjunctive antiepileptic therapy to a drug regimen that includes stiripentol, clobazam and valproate in a randomized, double-blind,…

WednesdayFeb 22, 2017 1:20 pm

NetworkNewsBreaks – Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Has ‘Buy’ Rating Reiterated by Aegis Capital

Noting Vanda Pharmaceuticals’ (NASDAQ: VNDA) recent financials and 2017 guidance, Aegis Capital Corp. has reiterated its 'Buy' rating and $24 price target on the company’s stock. Vanda reported net product sales for its melatonin receptor agonist, HETLIOZ®, at $71.7 million for full-year 2016, an increase of 62% compared to $44.3 million for the full year 2015. Fanapt®, the company’s atypical antipsychotic, brought in $74.3 million for the full year 2016, a 13% increase compared to $65.6 million in 2015. For the fourth quarter of 2016, Vanda reported non-GAAP net income of $3.6 million, compared to a non-GAAP net loss of…

TuesdayFeb 14, 2017 12:33 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $8 PT on Intellipharmaceutics International, Inc. (NASDAQ: IPCI)

Aegis Capital has reiterated its 'Buy' rating and $8 price target for Intellipharmaceutics International (NASDAQ: IPCI), citing expectations that the company will continue to make progress in 2017. In an earnings release last week, Intellipharmaceutics recapped its achievements in 2016, which included a license and commercial supply agreement with Mallinckrodt LLC to market, sell and distribute several of the company’s extended release drug product candidates (generic Seroquel XR®, generic Pristiq®, generic Lamictal® XR™). Intellipharmaceutics also secured tentative approval for generic Seroquel XR® with official launch planned for first half of 2017. Revenues for full-year 2016 were $2.2 million vs. $4.1…

MondayFeb 13, 2017 11:54 am

NetworkNewsBreaks – XOMA Corp. (NASDAQ: XOMA) Prices $25M Registered Offering; Shares Higher

XOMA (NASDAQ: XOMA) shares are up 14% mid-morning following news the company has agreed to sell 1.2 million shares of its common stock and 5,003 shares of convertible preferred stock directly to Biotechnology Value Fund, L.P. and certain of its affiliates (BVF) in a registered direct offering priced at $4.03 per share. The total number of shares of common stock issued upon conversion of all issued Series X Preferred Stock will be 5,003,000 shares. XOMA anticipates total gross proceeds from the offering will be approximately $25 million. Subject to customary closing conditions, the offering is expected to close on February…

ThursdayFeb 09, 2017 9:52 am

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Prices $5M Public Offering; Shares Lower

Moleculin Biotech (NASDAQ: MBRX) shares tumbled 20% at market open after the company priced an underwritten public offering of its securities. The offering is comprised of 3,710,000 units at a public offering price of $1.35 per unit. Moleculin anticipates gross proceeds of approximately $5 million. The offering is expected to close on or about February 14, 2017. To view the full press release, visit: http://nnw.fm/oN1sN About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s…

WednesdayFeb 08, 2017 12:22 pm

NetworkNewsBreaks – ViewRay, Inc. (NASDAQ: VRAY) Covered at Aegis with ‘Buy’ Rating, $11 PT

Aegis Capital Corp. recently initiated coverage of ViewRay (NASDAQ: VRAY), issuing a 'Buy' rating and $11 price target on the company's stock. ViewRay’s MRIdian® radiation therapy system is designed to address key restrictions of current external-beam radiation therapy technologies, and is the first of its kind to use real-time imaging that visibly defines the targeted tumor from the surrounding soft tissue and other critical organs. The company believes this will greatly improve the safety and efficacy of radiation therapy, leading to better results for patients. Most recently, the company announced that the Edogawa Hospital in Tokyo, Japan, purchased the system…

WednesdayFeb 08, 2017 12:11 pm

NetworkNewsBreaks – RGS Energy (NASDAQ: RGSE) Shares Sink following Pricing of $6M Public Offering

Shares of RGS Energy (NASDAQ: RGSE) are down 20% mid-morning after the company announced its securities purchase agreement for a registered offering of common stock and warrants. The “Primary Units” each consist of one share of Class A common stock (par value $0.0001) and a Series M Warrant to purchase common stock. The “Alternative Units” each consist of one prepaid Series N Warrant to purchase one share of common stock and a Series M Warrant to purchase common stock. The purchase price for a Primary Unit is $2.50 per unit and the purchase price for an Alternative Unit is $2.49…

MondayFeb 06, 2017 1:14 pm

NetworkNewsBreaks – Accuray, Inc. (NASDAQ: ARAY) Covered at Aegis Capital with ‘Buy’ Rating, $7 PT

Aegis Capital Corp. has initiated coverage of Accuray (NASDAQ: ARAY), issuing a 'Buy' rating and $7 price target on the company's stock. Accuray is a radiation oncology company with distinctive, innovative products specifically designed for image-guided radiosurgery and intensity-modulated radiation therapy - two rapidly growing market segments. The company’s most recent financial results, for the second fiscal quarter and six months ended December 31, 2016, show second-quarter gross orders of $78.5 million with net orders of $54.1 million totaling year-over-year growth of 17%, as well as an ending backlog increase of 16% year-over-year to $426.2 million. To learn more, visit…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Breaks Categories: Analyst Alerts